Latest News Archive

Please select Category, Year, and then Month to display items
Categories
UFS News Media Release Research
Years
2017 2018 2019 2020 2021 2022 2023 2024
Months
January February March April July May June August September October November December
Previous Archive
31 May 2023 | Story Sieraaj Ahmed | Photo Sonia Small

The University of the Free State (UFS) Chancellor, Prof Bonang Mohale, and UFS Rector and Vice-Chancellor, Prof Francis Petersen, recently hosted the UFS’s 38 th UFS Chancellor’s Distinguished Alumni Awards (CDAA) Dinner. The event took place in the Callie Human Centre on the UFS Bloemfontein Campus and honoured 10 outstanding UFS alumni for their achievements in both their personal and professional capacities.

“The UFS’s CDAA Awards are important to help represent those without a voice, thereby releasing better humans who care deeply for each other and are meaningfully connected, incredibly constructive citizens who are catalysts of change – to change us from humankind to kind humans, simply because kindness is the highest form of intelligence. To change us from important people to persons of significance – from taking to giving, as a new form of transformative philanthropy,” Prof Mohale told awardees and other UFS alumni who attended the dinner.

UFS alumni excelling in their various fields

Gerda Steyn, who recently made history by becoming the first woman to win the Two Oceans Marathon four consecutive times, was recognised as the Chancellor’s Distinguished Alumnus of the Year award winner. This is the highest honour bestowed upon an alumnus and celebrates someone who serves to inspire fellow alumni, current students, and the community at large. Steyn’s parents, Pieter and Trudie Steyn accepted the award on her behalf. (A full list of awardees can be found at the end of this story).

Prof Petersen applauded all the winners as well as UFS alumni everywhere who excel in their various fields. “Excellence is part of our DNA, and our valued alumni across the globe are the products of this. We believe the impact our alumni are making at every level should be continuously encouraged for the greater good, through recognition and celebration of achievements. This is why the Chancellor’s Distinguished Alumni Awards Ceremony has shed light on the impact of our exceptional alumni for the past 38 years and will continue to do so.”

He urged all alumni to learn more about Vision 130, an elaboration of the UFS’s strategic intent to reposition the institution ahead of 2034, when UFS will commemorate its 130th anniversary. “Vision 130 is centred around the pillars of academic excellence, quality, and impact; creating maximum societal impact with sustainable relationships; and establishing a diverse, inclusive, and equitable university. The alumni honoured this year are an embodiment of our Vision 130, and we congratulate them and look forward to the great achievements that are on the horizon for you and the rest of the UFS community.”

 

Dr Maryam Amra Jordaan - Cum Laude Award. Rene Images Uyleta Nel-Marias - Kovies Ambassador Award
   
Cum Laude Award winner, Dr Maryam Amra Jordaan, with Prof Francis Petersen, UFS Rector and Vice-Chancellor, and Prof Bonang Mohale, UFS Chancellor, at the 38th Chancellor’s Distinguished Alumni Awards Dinner. Kovsie Ambassador Award winner, Uyleta Nel-Marais, with Prof Francis Petersen, UFS Rector and Vice-Chancellor, and Prof Bonang Mohale, UFS Chancellor, at the 38th Chancellor’s Distinguished Alumni Awards Dinner.


38th Chancellor’s Distinguished Alumni Awards (CDAA) winners – 20 May 2023

Chancellor’s Distinguished Alumnus of the Year

GERDA STEYN

 

Young Alumnus of the Year

SEBABATSO TSAOANE

 

Executive Management Award

PROF FRANCOIS STRYDOM

PROF ABDON ATANGANA

 

Cum Laude Award

DR SOLOMON WERTA

DR MARYAM AMRA JORDAAN

PROF ANDRIES STULTING

 

Kovsie Ambassador Award

REHAN GREEFF

UYLETA NEL-MARAIS

ELIZABETH MOKGOSI

 

Click to view documentView Full programme

 

Watch the live stream recording:


 

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept